Due to the results, we postulate that also other inflammatory disease conditions for instance septic shock [178], DIC [178], atherogenesis [179] or tumor neoangiogenesis [180,181] might benefit from an adapted treatment strategy based on the prototypic SLC1. Here, MCHR1 is linked to neoplasm.